MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation
Yi-Long Wu,Qing Zhou,Xiaoqing Liu,Li Zhang,Jianying Zhou,Lin Wu,Tong-Tong An,Ying Cheng,Xin Zheng,Bei Hu,Ji Jiang,Xin Fang,Wanhong Xu,Xiao Xu +13 more
Reads0
Chats0
About:
This article is published in Journal of Thoracic Oncology.The article was published on 2017-01-01 and is currently open access. It has received 11 citations till now. The article focuses on the topics: non-small cell lung cancer (NSCLC) & EGFR inhibitors.read more
Citations
More filters
Journal ArticleDOI
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu,Jin-Yuan Shih +1 more
TL;DR: Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment.
Journal ArticleDOI
Third generation EGFR TKIs: current data and future directions.
Chee Seng Tan,Nesaretnam Barr Kumarakulasinghe,Yiqing Huang,Yvonne Li'en Ang,Joan Rou-En Choo,Boon Cher Goh,Boon Cher Goh,Ross A. Soo,Ross A. Soo +8 more
TL;DR: Osimertinib under FLAURA study had been shown to have better progression-free survival over first generation EGFR TKI in the first line setting and likely will become the new standard of care.
Journal ArticleDOI
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.
Rashmi R. Shah,Devron R. Shah +1 more
TL;DR: It is noteworthy that newer EGFR-TKIs that spare wild-type EGFR are associated with fewer dermatological reactions, and available data reviewed herein indicate that these newer agents associated with the aforementioned adverse effects typical of earlier agents are also susceptible to resistance due to tertiary mutations.
Journal ArticleDOI
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Rui-Fang Dong,Miao-Lin Zhu,Ming-Ming Liu,Yi-Ting Xu,Liu-Liu Yuan,Jing Bian,Yuan-Zheng Xia,Yuan-Zheng Xia,Ling-Yi Kong +8 more
TL;DR: In this paper, the authors discuss the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, highlight the development of targeted drugs to overcome EGFR mutation-mediated resistance, and predict the promising directions for development of novel candidates.
Journal ArticleDOI
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
Zhiyong Liang,Ying Cheng,Yuan Chen,Yanping Hu,Wei-ping Liu,You Lu,Jie Wang,Wang Ye,Gang Wu,Jianming Ying,Helong Zhang,Xu-Chao Zhang,Yi-Long Wu +12 more
TL;DR: Though there are several platforms for EGFR mutation detection, highly sensitive platforms for clinical applicability as companion diagnostics for ctDNA based testing are emerging, real-time monitoring of these genetic alterations is mandate for planning treatment strategies.